Pfizer Eyes InnoPharma, Acquisition to Boost Injectables Biz - Analyst Blog


Pfizer Inc. ( PFE ) signed a deal to acquire InnoPharma, Inc., a company that specializes in the development of hard-to-make, differentiated, sterile injectables. The acquisition, which could result in Pfizer shelling out up to $360 million, is scheduled to close in the third quarter.

Pfizer will make an upfront payment of $225 million and could end up paying up to $135 million on the achievement of certain milestones. With this acquisition, the company will gain 10 approved generic products plus a pipeline of more than 30 injectable and ophthalmic products. These include products for areas like cancer and central nervous disorders. Once the acquisition is completed, Pfizer's sterile injectables portfolio will increase to 73 products.

Pfizer is not the only company to announce an acquisition to boost its injectable business. Late last year, Mylan ( MYL ) boosted its injectables segment through the acquisition of the Agila injectables businesses from Strides Arcolab Limited in a deal worth up to $1.75 billion.

While the InnoPharma acquisition will strengthen Pfizer's injectables segment, the company needs to boost its pipeline and bring new products to market to drive growth. With this in mind, the company had launched a proposal to acquire UK based AstraZeneca ( AZN ). The acquisition, had it gone through, would have boosted Pfizer's pipeline specifically for immuno-oncology drugs, and would have resulted in a more efficient tax structure. However, AstraZeneca was not game and Pfizer subsequently abandoned its plans to acquire AstraZeneca.

Pfizer is a Zacks Rank #2 (Buy) stock. We expect the company to continue pursuing bolt-on acquisitions and in-licensing deals to boost its portfolio. Some equally well-ranked stocks in the pharma sector include AstraZeneca and Allergan ( AGN ).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ASTRAZENECA PLC (AZN): Free Stock Analysis Report

PFIZER INC (PFE): Free Stock Analysis Report

ALLERGAN INC (AGN): Free Stock Analysis Report

MYLAN INC (MYL): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ, Inc.

This article appears in: Investing , Business , Stocks

Referenced Stocks: AZN , PFE , AGN , MYL

More from

Related Videos



Most Active by Volume

  • $15.38 ▼ 1.09%
  • $110.38 ▲ 0.73%
  • $104.01 ▲ 1.75%
  • $6.3801 ▼ 53.60%
  • $4.25 ▲ 4.94%
  • $15.91 ▲ 7.72%
  • $4.64 ▲ 11.27%
  • $25.47 ▲ 1.11%
As of 10/2/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by